regulation is the sole category represented across all 2 tracked stories. CNBC is the most frequent co-covered peer, appearing in 1 of the 2 tracked stories. Source depth averages 5.5 original sources per story, versus 2.4 across the same-window beat baseline.
Figures are computed live from our source-verified story record
— see our methodology for how impact and
sentiment are derived.
What the coverage shows about Idaho
regulation is the sole category represented across all 2 tracked stories. CNBC is the most frequent co-covered peer, appearing in 1 of the 2 tracked stories. Source depth averages 5.5 original sources per story, versus 2.4 across the same-window beat baseline. Across a 28-day span, the pace is roughly 0.5 stories per week. The 6 average consequence score is above the beat benchmark of 5.8 in the same window. We currently track 2 Healthcare stories that mention Idaho, published between July 20, 2026 and August 16, 2026.
Stories tracked
2
Per week
0.5
Sources per story
5.5
Computed from the 2 stories linked to this entity, with beat comparisons drawn from all 302 Healthcare stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Appears alongside
Other entities that clear the same relevance threshold in stories also covering Idaho. Shared-story counts are live from our verified record — not editorial picks.
Health systems and health IT vendors building around CMS's hemp-derived cannabinoid initiative are on contested regulatory ground. A successful federal challenge could stay or remand the program, changing compliance and reimbursement calculations.
Voters in four states will determine reproductive healthcare access this November, with Idaho's measure potentially lifting a ban that lacks a health exception and Missouri's proposal threatening to reimpose restrictions, directly affecting patient outcomes and provider services.